Published on 21/12/2025

Best Practices for Documenting SDV in Clinical Monitoring Reports

Source Data Verification (SDV) is a core function of clinical monitoring. However, even perfectly executed SDV can lose its value if not appropriately documented in the Monitoring Visit Report (MVR). Regulatory authorities such as the USFDA and CDSCO emphasize that proper documentation of SDV activities is essential to ensure data integrity, protocol compliance, and audit readiness. This tutorial explains how CRAs should capture SDV findings in a clear, structured, and GCP-compliant format.

Table of Contents

What Is SDV Documentation in Monitoring Reports?

SDV documentation refers to the section within the MVR where the CRA describes the extent of SDV performed during a site visit, the findings, any discrepancies noted, resolution status, and comments on overall data quality. It serves as a traceable record for sponsors, QA teams, and regulatory auditors.

Where Should SDV Appear in the Monitoring Visit Report?

Most MVR templates include dedicated sections or subheadings such as:

Source Data Verification (SDV)
Data Quality and Integrity
CRF vs Source Review
Query Resolution and Data Entry Timeliness

What to Include in SDV Documentation

1. Scope and Subjects Covered

Start with a summary of which subjects and visits were verified:

“SDV was performed for Subjects 001, 003, and 005 (Visit 2 and

3).”

“Focus was placed on screening, informed consent, AE reporting, and dosing records.”

2. Percentage or Level of SDV Completed

“100% SDV was completed for critical fields as outlined in the SDV Plan.”
“Approximately 50% random SDV was performed for non-critical labs and demographic data.”

3. Summary of Observations

Note the quality and consistency of the data:

“No major discrepancies were noted between the source documents and CRF entries.”
“One discrepancy found in Subject 003’s dosing date was immediately queried and corrected.”

4. Query and Discrepancy Management

“Two data queries were raised for Subject 005 regarding AE term spelling and missing lab date.”
“Site acknowledged both queries during the visit and agreed to correct within 24 hours.”

5. Overall SDV Assessment

This narrative should be evaluative:

“The site maintains high-quality source documentation and entered CRF data in a timely manner.”
“No concerns were identified regarding GCP or protocol compliance in the reviewed subjects.”

Using SDV Checklists and Logs

To maintain audit trails and ensure consistency, CRAs should also complete SDV checklists/logs. These should be referenced in the MVR:

“See attached SDV checklist in trip report appendix.”
“Discrepancies noted were logged in the site SDV tracker maintained in the CTMS.”

Tips for Consistent SDV Documentation

Follow your organization’s Pharma SOP documentation standards
Use structured language for clarity and traceability
Be objective—do not make assumptions or speculative comments
Document even when no issues were found (“No discrepancies noted”)

CRA Example Entry

Example:

“SDV was performed for 3 subjects across screening and follow-up visits. Critical fields such as informed consent, eligibility criteria, AE/SAE, and IP administration were verified against source documents. One minor data discrepancy (date of AE onset) was noted, queried, and resolved on-site. Overall, the data was accurate, timely, and well-documented.”

Incorporating CTMS and EDC Tools

CRAs should leverage CTMS systems to document which pages and fields were verified and auto-sync with monitoring reports where possible. Some systems allow flagging SDV completion status per subject, which enhances oversight by the sponsor and QA teams. For more on monitoring documentation, refer to Stability Studies.

Aligning with Regulatory Guidelines

Agencies like the EMA expect sponsors to maintain documented proof of SDV scope and execution. Inadequate SDV records have led to observations during site inspections. Use SDV documentation as part of your inspection readiness package.

Conclusion

Accurate and detailed SDV documentation is vital for clinical trial success. It serves as evidence of compliance, facilitates effective communication with sponsors, and prepares sites for regulatory audits. CRAs should treat MVR entries related to SDV not just as formality but as critical records that uphold trial integrity and transparency.